Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bexmarilimab, an antibody targeting STAB1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Giloralimab, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zeluvalimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Avizakimab, an antibody targeting IL21.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Benufutamab, an antibody targeting TNFRSF10B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lonigutamab, an antibody targeting IGF1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nivatrotamab, an antibody targeting GD2 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Omodenbamab, an antibody targeting Staphylococcus aureus Protein A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Garivulimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Grisnilimab, an antibody targeting CD7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Letaplimab, an antibody targeting IAP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rimteravimab, an antibody targeting SARS-CoV-2 Spike RBD.